Mauricio E Gamez1, Manuj Agarwal2, Kenneth S Hu3, John N Lukens4, Louis B Harrison5. 1. Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, U.S.A. Gamez.mauricio@mayo.edu. 2. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, U.S.A. 3. Department of Radiation Oncology, New York University, New York, NY, U.S.A. 4. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, U.S.A. 5. Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, U.S.A.
Abstract
AIM: To analyze the outcomes using the hypofractionated palliative radiotherapy regimen "QUAD-Shot" with concurrent radiosensitizing chemotherapy for advanced head and neck cancer. MATERIALS AND METHODS: We analyzed twenty-one patients with newly-diagnosed or recurrent head and neck cancer treated with palliative hypofractionated concurrent chemoradiation using the QUAD-Shot regimen. RESULTS: All patients received at least one cycle of RT, with sixteen patients (76%) completing all three cycles. 85.7 % of patients had objective response to therapy with five patients (23.8%) demonstrating complete response (CR) and thirteen patients (61.9%) demonstrating partial response (PR). Palliation of symptoms was achieved in all (100%) of the sixteen patients that completed the three cycles. Median overall survival and median progression-free survival were 7 and 4 months, respectively. CONCLUSION: QUAD-Shot palliative radiation therapy coupled with radiosensitizing chemotherapy is efficacious and well-tolerated in patients with newly-diagnosed or recurrent head and neck cancer not amenable to curative therapy. Copyright
AIM: To analyze the outcomes using the hypofractionated palliative radiotherapy regimen "QUAD-Shot" with concurrent radiosensitizing chemotherapy for advanced head and neck cancer. MATERIALS AND METHODS: We analyzed twenty-one patients with newly-diagnosed or recurrent head and neck cancer treated with palliative hypofractionated concurrent chemoradiation using the QUAD-Shot regimen. RESULTS: All patients received at least one cycle of RT, with sixteen patients (76%) completing all three cycles. 85.7 % of patients had objective response to therapy with five patients (23.8%) demonstrating complete response (CR) and thirteen patients (61.9%) demonstrating partial response (PR). Palliation of symptoms was achieved in all (100%) of the sixteen patients that completed the three cycles. Median overall survival and median progression-free survival were 7 and 4 months, respectively. CONCLUSION: QUAD-Shot palliative radiation therapy coupled with radiosensitizing chemotherapy is efficacious and well-tolerated in patients with newly-diagnosed or recurrent head and neck cancer not amenable to curative therapy. Copyright
Authors: Jiahua Lyu; Tao Liu; Tao Li; Fang Li; Qifeng Wang; Jie Wang; Yongtao Han; Junchao Wang; Jun Zhang; Lin Peng; Jinyi Lang Journal: Cancer Med Date: 2019-05-22 Impact factor: 4.452
Authors: Amy B Leming; Andrea L Johnston; Greg A Krempl; Evan J Fowle; Daniel J Morton; Christina E Henson Journal: J Otolaryngol Head Neck Surg Date: 2022-10-04
Authors: Alexander Fabian; Justus Domschikowski; Markus Hoffmann; Oliver Weiner; Claudia Schmalz; Jürgen Dunst; David Krug Journal: Front Oncol Date: 2021-06-04 Impact factor: 6.244